Ultragenyx Pharmaceutical (NASDAQ:RARE) Lifted to Buy at BidaskClub

BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a buy rating in a research note issued to investors on Tuesday, BidAskClub reports.

RARE has been the topic of several other reports. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a hold rating to a buy rating in a research report on Thursday, July 18th. Morgan Stanley lowered their price target on shares of Ultragenyx Pharmaceutical from $83.00 to $79.00 and set an overweight rating on the stock in a research report on Friday, August 2nd. Wedbush reiterated an outperform rating and issued a $75.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, August 2nd. JPMorgan Chase & Co. reiterated a buy rating and issued a $75.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Monday, August 5th. Finally, Zacks Investment Research upgraded shares of Ultragenyx Pharmaceutical from a hold rating to a buy rating and set a $73.00 price target on the stock in a research report on Tuesday, April 23rd. Two investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of $75.93.

Shares of RARE opened at $56.87 on Tuesday. The company has a current ratio of 9.32, a quick ratio of 9.14 and a debt-to-equity ratio of 0.04. The firm’s 50-day moving average is $60.27 and its two-hundred day moving average is $62.08. Ultragenyx Pharmaceutical has a twelve month low of $37.44 and a twelve month high of $90.98. The firm has a market capitalization of $3.53 billion, a P/E ratio of -7.70 and a beta of 2.16.



Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.72) EPS for the quarter, beating the consensus estimate of ($1.73) by $0.01. The business had revenue of $24.15 million for the quarter, compared to analyst estimates of $22.16 million. Ultragenyx Pharmaceutical had a negative net margin of 527.49% and a negative return on equity of 49.84%. The company’s quarterly revenue was up 88.8% on a year-over-year basis. During the same period in the prior year, the business earned ($1.06) earnings per share. Analysts predict that Ultragenyx Pharmaceutical will post -7.04 EPS for the current year.

In related news, EVP Karah Herdman Parschauer sold 1,489 shares of the firm’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $63.01, for a total transaction of $93,821.89. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 7.80% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in RARE. NumerixS Investment Technologies Inc acquired a new stake in Ultragenyx Pharmaceutical during the second quarter worth approximately $25,000. Cutler Group LP acquired a new stake in Ultragenyx Pharmaceutical during the second quarter worth approximately $31,000. Meeder Asset Management Inc. boosted its position in Ultragenyx Pharmaceutical by 321.1% during the first quarter. Meeder Asset Management Inc. now owns 598 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 456 shares during the last quarter. First Mercantile Trust Co. boosted its position in Ultragenyx Pharmaceutical by 101.0% during the first quarter. First Mercantile Trust Co. now owns 985 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 495 shares during the last quarter. Finally, Smith Asset Management Group LP boosted its position in Ultragenyx Pharmaceutical by 22.6% during the second quarter. Smith Asset Management Group LP now owns 1,680 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 310 shares during the last quarter. Hedge funds and other institutional investors own 99.55% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Recommended Story: Cost of Capital

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.